Protagonist's Q3 swings to a $220M profit on Takeda payments; royalty story still ahead

The quarter in numbers

Protagonist Therapeutics reported third-quarter 2026 license and collaboration revenue of $274.4 million, against $4.7 million a year earlier. Income from operations was $218.3 million, compared with a loss of $46.4 million in Q3 2025. Net income was $220.0 million, or $3.32 per basic share and $3.07 per diluted share, versus a net loss of $39.3 million, or $0.62 per share.

The nine-month picture is similar. Revenue was $544.3 million (nine months of 2025: $38.6 million), and net income was $386.6 million, or $5.88 basic and $5.43 diluted, against a loss of $85.8 million. The swing is large, but it comes from milestone and opt-out payments rather than product sales.

What drove revenue: one Takeda event

The company said the FDA approval of MIMRYLO (rusfertide), announced August 28 and secured by partner Takeda, triggered $275 million in payments: a $200 million opt-out payment and a $75 million approval milestone. Protagonist recognized $266.6 million of that in the quarter on a proportional basis. The remaining $7.8 million of Q3 revenue came from development services under the Takeda agreement and other revenues. The release does not explain how the roughly $8 million difference between the $275.0 million earned and the $266.6 million recognized is treated.

The company said the $275.0 million was received in cash in October 2026. It is therefore not in the September 30 cash balance, which makes the next balance sheet a notable one.

For the nine months, $460.5 million was proportional revenue recognized from Takeda and $33.8 million was development services. The company also booked a $50.0 million milestone from Johnson & Johnson in Q1 2026 on FDA approval of ICOTYDE (icotrokinra).

The release gives no ICOTYDE royalty figure or partner sales figure. The company said Q3 was ICOTYDE's second full quarter of U.S. sales and described the launch as 'continued strong', but investors cannot size royalty revenue from this document. Any ICOTYDE royalty sits inside the unspecified 'other revenues'.

Costs: modest growth, with a step-up signaled

R&D expense was $41.3 million, up from $40.0 million. The company attributed the rise to clinical development and pre-clinical discovery programs, partly offset by lower rusfertide spending on the Phase 3 VERIFY trial. G&A was $13.7 million versus $11.1 million, which the company tied to stock-based compensation and other personnel costs. Total operating expense was $56.1 million, versus $51.1 million.

The quarter also showed new lines. Cost of revenue was $1.1 million, with none in the prior-year periods. Income tax expense was $6.6 million, with none in Q3 2025. Interest income was $8.3 million, versus $7.0 million.

The company gave no revenue or earnings guidance, but it did guide on spending. It expects R&D to increase for the remainder of the year compared with the prior 2026 quarters. It named the drivers: PN-881's move into a comprehensive Phase 2 psoriasis program, clinical manufacturing and CMC investment including at-risk expenditure for PN-477o, PN-458 and PN-8047, additional discovery programs, and higher headcount and stock-based compensation.

Balance sheet and capital return

Cash, cash equivalents and marketable securities were $834.6 million at September 30, 2026, up from $646.0 million at year-end 2025. The company announced a share repurchase program of up to $300 million on September 8. It said it intends to fund buybacks from its cash and securities, as well as royalties and other payments under the Takeda and Johnson & Johnson collaborations. Timing and amount will depend on market conditions, alternative capital deployment opportunities and other factors, so the release sets no pace.

The terms of the two partnerships frame the longer-term economics. For MIMRYLO, following Protagonist's April 2026 opt-out election, Takeda holds exclusive worldwide rights. Protagonist is eligible for tiered royalties of 14% to 29%, about 21% weighted-average at $1.5 billion in annual net sales, plus up to $875 million in further milestones. For ICOTYDE, royalties run 6% to 10% on global net sales, about 7.25% weighted-average at $4 billion in annual net sales, with 10% on incremental sales above that, plus up to $580 million in additional milestones.

Pipeline and regulatory catalysts

On regulatory progress, the company said ICOTYDE won approvals in China, Japan and the EU for psoriasis during Q3, following US approval in March 2026. MIMRYLO was also approved in the United Arab Emirates on September 30. Published data included VERIFY in the Journal of Clinical Oncology on October 13 and the Phase 2 ANTHEM-UC study in the New England Journal of Medicine on October 14. ICOTYDE remains in development for psoriatic arthritis, ulcerative colitis and Crohn's disease.

The wholly owned pipeline sets the next dates. PN-881, an oral IL-17 antagonist, completed Phase 1, with the company reporting trough concentrations several-fold above targeted IC90 values and no serious adverse events. A Phase 2b dose range-finding study in plaque psoriasis is planned for early Q1 2027. PN-8047, an oral hepcidin functional mimetic, is slated for Phase 1 in Q1 2027. Oral PN-477o, the triple agonist, is expected to start Phase 1 in the first half of 2027, after the company chose to prioritize it over the subcutaneous version. PN-458o, a dual agonist, is expected to start Phase 1 in the second half of 2027.

What to watch next

First, the Q4 report should show the October cash receipt, the remaining revenue recognition from the Takeda payments, and whether any buyback activity begins. Second, the first clear read on ICOTYDE-linked royalties, which this release does not isolate. Third, the R&D ramp the company flagged, and how it compares with the $41.3 million quarterly level. Finally, whether PN-881's Phase 2b starts on schedule in early Q1 2027, as the company's wholly owned programs carry its post-partnership strategy.